Blog

Kamada Phase II/III for Inhaled AAT

October 14, 2012 | Comments are closed

Kamada has obtained FDA approval for a Phase II/III clinical trial of AAT-IH, the inhalable version of its AAT drug for treatment of Alpha-1 antitrypsin deficiency for the treatment of congenital emphysema. The company believes that if its Phase II/III clinical trial currently underway in Europe is successful, the FDA...

Can-Fite Phase 2-3 Psoriasis Study

October 14, 2012 | Comments are closed

Can-Fite BioPharma is continuing patient enrollment in its Psoriasis Phase 2/3 clinical study with CF101. This decision follows an interim analysis of safety and efficacy data from the first 103 patients who completed 24 weeks of treatment in the trial. The positive clinical effects of the CF101-2 mg BID dose...

OrbiMed Invests $5 M in cCam

October 14, 2012 | Comments are closed

The OrbiMed Israel Fund has completed a $5 million investment in cCam. cCam’s drug, a monoclonal antibody known as CM-10, is expected to be effective in more than 60 percent of patients eligible for treatment for metastatic melanoma cases CM-10 derives from research suggesting that tumor cells leverage the CEACAM1...

Given Imaging Acquires SmartPill

October 14, 2012 | Comments are closed

Given Imaging has acquired from The SmartPill Corporation, a U.S. based-company, for $6 million. The SmartPill® is an ingestible capsule that uses sensor technology to measure pH, pressure and temperature in the GI tract. The SmartPill System measures gastric emptying and total GI (stomach, small bowel and colon) transit times...

Texas Hospital Buys Mazor Robotics System

October 14, 2012 | Comments are closed

Mazor Robotics has sold a surgical robotic system to Humble Surgical Hospital in Humble, Texas. Humble Surgical Hospital is a multispecialty surgical hospital. Renaissance, Mazor Robotics’ surgical guidance system for spine procedures, is used for spine surgery from freehand operations to highly-accurate, state-of-the-art procedures, with less radiation – even for...